NEW YORK (GenomeWeb News) – Illumina said today that its noninvasive prenatal testing subsidiary Verinata Health has signed an exclusive agreement with Teva Pharmaceutical Industries to commercialize its Verifi test in Israel.

Under the terms of the five-year agreement, Teva will be the exclusive distributor of Verifi in Israel. All tests will be run in Verinata's CLIA-certified laboratory in California, while Israel's Clalit Health Services will provide reimbursement for Verifi through supplemental insurance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.